Press Release Paris – December 10, 2025 - EUROAPI today announces that, following the resignation of Rodolfo Savitzky from his position as Independent Director (effective December 31, 2025)1, and upon the recommendation of the Nominations and Compensation Committee, the Board of Directors has decided to co-opt Tristan Imbert as Independent Director, subject to the vote of EUROAPI Shareholders’ meeting on May 27, 2026. Tristan Imbert will be appointed Chair of the Audit Committee, effective January 01, 20 ...

Core Insights - EUROAPI officially launched its innovation programs under the Health IPCEI initiative, aimed at enhancing pharmaceutical sovereignty in Europe [1][3] - The project, named "Med4Cure," is supported by the European Commission and involves collaboration with various start-ups, academic institutions, and industry partners [2][3] Company Overview - EUROAPI is a leading player in active pharmaceutical ingredients, with approximately 200 products in its portfolio and a focus on sustainable solutions [5][6] - The company operates five manufacturing sites in Europe and serves customers in over 80 countries [6] Innovation Programs - Med4Cure will co-finance R&D activities focusing on three strategic areas: corticosteroids, nanocrystals, and macrolide antibiotics [4] - The global market for EUROAPI's corticosteroids was estimated at 657 million euros in 2024 [4] Funding and Support - In June 2024, EUROAPI was selected to share up to 1 billion euros in public funding under the Health IPCEI [3] - A contractual agreement was signed in July 2025, providing up to 140 million euros in public aid under the France 2030 investment plan [3]

Government Initiatives & Policy - Aims to establish a strategic active pharmaceutical ingredient (API) reserve to bolster domestic manufacturing [2] - Calls for creating a list of drugs critical to America's health and security interests [1] - Health and Human Services (HHS), the Veterans Affairs (VA), and the Department of Defense (DoD) to issue long-term contracts to buy needed medicines, stabilizing demand [3][9] - Considers pharmaceutical tariffs under Section 232 due to national security concerns [6][8] Supply Chain & Manufacturing - Focuses on fast-tracking advanced continuous manufacturing to reduce costs and waste in pharmaceutical production [4][5] - Aims to reduce reliance on China and India, which currently supply 60% of US API and medicines [5] - Seeks to move from extreme vulnerability to "America first" in pharmaceutical manufacturing [10] Investment Opportunities - Presents significant investment opportunities for those who can identify potential winners in the pharmaceutical sector [7] - Executive order is a follow-up to previous efforts to bring pharma manufacturing back to the US [6] Risks & Challenges - Acknowledges the need for careful administration to transition to pharmaceutical independence [10] - Highlights the vulnerability of relying on foreign sources for essential medicines, citing China's past threats [8]

Core Insights - EUROAPI has signed a share purchase agreement for the sale of 100% of EUROAPI UK Ltd, which operates the Haverhill manufacturing site, to Particle Dynamics [1][2] - The divestment is part of EUROAPI's strategy to optimize its industrial footprint and advance its FOCUS-27 transformation plan, enhancing efficiency and focus on its strategic network [2] - The Haverhill site generated approximately 35 million euros in net sales in 2024, with nearly 80% attributed to Sanofi [2] Company Overview - EUROAPI is a leading player in active pharmaceutical ingredients, offering around 200 products and developing innovative molecules through its Contract Development and Manufacturing Organization (CDMO) activities [3] - The company operates six manufacturing sites in Europe and supplies customers in over 80 countries, emphasizing high-quality API manufacturing [4] - EUROAPI is listed on Euronext Paris under the ticker EAPI [4]

Core Viewpoint - IMCD N.V. has announced the acquisition of 100% of the shares in Trichem Healthcare Private Limited, Trichem Lifesciences Limited, and Chemistry & Health FZ LLC, enhancing its portfolio in the life-sciences industry, particularly in active pharmaceutical ingredients [1][4]. Company Overview - IMCD is a global leader in the distribution and formulation of specialty chemicals and ingredients, headquartered in Rotterdam, The Netherlands [5]. - In 2024, IMCD reported revenues of EUR 4,728 million and employed over 5,100 staff [6]. Trichem Overview - Trichem, founded in 1998 and based in Mumbai, India, specializes in supplying high-quality active pharmaceutical ingredients and pharmaceutical intermediates, along with regulatory assistance for the pharmaceutical markets in India [2]. - The company operates with 36 employees and generated annual revenue of approximately INR 1.7 billion (around EUR 18 million) for the financial year ending 31 March 2025, with 33% of this revenue derived from commission income [3]. Strategic Importance - The acquisition is positioned to strengthen IMCD's presence in the Indian market, which is a major supplier of generic drugs globally, and to leverage Trichem's market expertise and industry relationships [4].